Patent ID: 8877900

Claim:
An isolated PCSK9-specific antagonist which comprises: (a) heavy chain variable region comprising CDR1, CDR2 and CDR3 sequence, wherein (i) the CDR1 sequence is selected from the group consisting of: SEQ ID NO: 189 and residues 4-13 of SEQ ID NO: 183; (ii) the CDR2 sequence is selected from the group consisting of: SEQ ID NO: 68 and residues 4-20 of SEQ ID NO: 68; and (iii) the CDR3 sequence is selected from the group consisting of: SEQ ID NO: 5 and residues 4-12 of SEQ ID NO: 5 and (b) a light chain variable region comprising CDR1, CDR2 and CDR3 sequence, wherein (i) the CDR1 sequence is selected from the group consisting of: SEQ ID NO: 349 and residues 4-14 of SEQ ID NO: 349; (ii) the CDR2 sequence is selected from the group consisting of: SEQ ID NO: 339 and residues 4-10 of SEQ ID NO: 335; and (iii) the CDR3 sequence is selected from the group consisting of: SEQ ID NO: 301 and residues 4-13 of SEQ ID NO: 301; said antagonist which inhibits human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%.